The Credit Agreement requires Whiting to maintain a leverage ratio of less than or equal to 3.50 to 1.00.
The Credit Agreement also contains customary affirmative and negative covenants, including, among other things, as to compliance with laws (including environmental laws and anti-corruption laws), delivery of quarterly and annual financial statements, conduct of business, maintenance of property, maintenance of insurance, restrictions on the incurrence of liens, indebtedness, asset dispositions, fundamental changes, restricted payments, and other customary covenants.
Additionally, the Credit Agreement contains customary events of default and remedies for credit facilities of this nature. If Whiting does not comply with the financial and other covenants in Credit Agreement, the Lenders may, subject to customary cure rights, require immediate payment of all amounts outstanding under the Credit Agreement and any outstanding unfunded commitments may be terminated. The foregoing description of the Credit Agreement is qualified in its entirety by reference to the full text of the Credit Agreement, a copy of which is attached hereto as Exhibit 10.1 and is incorporated herein by reference.
Guarantee and Security of the Credit Facilities
The obligations under the Exit Credit Facility are guaranteed by Whiting and certain of Whiting’s subsidiaries (collectively, the “Guarantors”) and secured by substantially all of their assets. On the Effective Date, the Guarantors entered into a guaranty and collateral agreement in favor of the Agent, for the benefit of the secured parties thereunder, pursuant to which the Guarantors guaranteed the payment and performance of all indebtedness and liabilities arising pursuant to, or in connection with, the Credit Agreement and granted a first lien security interest in all of the collateral described therein.
Warrant Agreements
On the Effective Date and pursuant to the Plan, Whiting entered into (i) a Warrant Agreement (the “Series A Warrant Agreement”) with Computershare Inc. and Computershare Trust Company, N.A., as warrant agent (collectively, the “Warrant Agent”), which provides for Whiting’s issuance of up to an aggregate of 4,837,821 Series A warrants (the “Series A Warrants”) to purchase outstanding common stock, par value $0.001 per share, of Whiting, as reorganized pursuant to and under the Plan (the “New Common Stock”) to former holders of Existing Common Stock (as defined below) on the Effective Date in accordance with the terms of the Plan, the Confirmation Order and the Series A Warrant Agreement and (ii) a Warrant Agreement (the “Series B Warrant Agreement” together with the Series A Warrant Agreement, the “Warrant Agreements”) with the Warrant Agent, which provides for Whiting’s issuance of up to an aggregate of 2,418,910 Series B warrants (the “Series B Warrants” together with the Series A Warrants, the “Warrants”) to purchase New Common Stock to former holders of Existing Common Stock on the Effective Date in accordance with the terms of the Plan, the Confirmation Order and the Series B Warrant Agreement.
The Series A Warrants are exercisable from the date of issuance until 5:00 p.m., New York time, on the fourth anniversary of the Effective Date, at which time, all unexercised Series A Warrants will expire, and the rights of the holders of such Series A Warrants to purchase New Common Stock will terminate. The Series A Warrants are initially exercisable for one share of New Common Stock per Series A Warrant at an initial exercise price of $73.44 per Series A Warrant (the “Series A Exercise Price”).
The Series B Warrants are exercisable from the date of issuance until 5:00 p.m., New York time, on the fifth anniversary of the Effective Date, at which time, all unexercised Series B Warrants will expire, and the rights of the holders of such Series B Warrants to purchase New Common Stock will terminate. The Series B Warrants are initially exercisable for one share of New Common Stock per Series B Warrant at an initial exercise price of $83.45 per Series B Warrant (the “Series B Exercise Price” together with the Series A Exercise Price, the “Exercise Prices”).
Pursuant to the Warrant Agreements, no holder of a Warrant, by virtue of holding or having a beneficial interest in a Warrant, will have the right to vote, receive dividends, receive notice as stockholders with respect to any meeting of stockholders for the election of Whiting’s directors or any other matter, or exercise any rights whatsoever as a stockholder of Whiting unless, until and only to the extent such holders become holders of record of shares of New Common Stock issued upon settlement of Warrants.
3